Kumar Patel, MD
Family Medicine · Bloomfield, NJNPI 1952898140
Payments from drug & device makers
Across 52 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$216
- Medtronic$165
- Inari Medical, Inc.$133
- Abiomed$132
- VYNE Pharmaceuticals Inc.$125
- Boehringer Ingelheim$112
- plus $638 from 15 others
What the payments were for
- Food & beverage$1,521100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $216 |
| Medtronic | 1 | $165 |
| Inari Medical, Inc. | 1 | $133 |
| Abiomed | 1 | $132 |
| VYNE Pharmaceuticals Inc. | 1 | $125 |
| Boehringer Ingelheim | 7 | $112 |
| GSK | 6 | $98 |
| Biotronik Inc. | 1 | $79 |
| Boston Scientific | 1 | $78 |
| Lilly USA, LLC | 4 | $66 |
| Amgen | 4 | $65 |
| Exact Sciences | 3 | $58 |
| Abbott | 3 | $47 |
| Pfizer | 2 | $30 |
| Novartis | 1 | $20 |
| Bavarian Nordic A/s | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$165
- FLOWTRIEVER CATHETER, S$133
- CT THROMBECTOMY SYSTEM KIT$133
- Impella$132
- ZILXI$125
How this compares
$1,521 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 124 | $135,781 |
| JardianceEmpagliflozin | 142 | $127,398 |
| JanuviaSitagliptin Phosphate | 76 | $87,508 |
| EliquisApixaban | 84 | $81,087 |
| MounjaroTirzepatide | 50 | $66,205 |
| OzempicSemaglutide | 34 | $48,193 |
| RybelsusSemaglutide | 26 | $46,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $41,492 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 31 | $40,900 |
| TradjentaLinagliptin | 43 | $39,715 |
| ProliaDenosumab | 18 | $30,546 |
| EntrestoSacubitril/Valsartan | 14 | $24,117 |
| XareltoRivaroxaban | 29 | $23,101 |
| JanumetSitagliptin Phos/Metformin Hcl | 29 | $22,302 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $12,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Glyxambi | $112 | $219,412229 claims |
| AstraZenecaFarxiga, Symbicort | $216 | $141,411138 claims |
| PfizerEliquis, Abrysvo | $30 | $86,492101 claims |
| Lilly USA, LLCMounjaro | $66 | $66,20550 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $98 | $49,75867 claims |
| AmgenProlia | $65 | $30,54618 claims |
| NovartisEntresto | $20 | $24,11714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Bloomfield
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.